When does the diazepam patent expire?
Diazepam is an older medicine that entered the market decades ago, so patents tied to the original invention and early formulations are generally long expired. Exact “patent expiry” dates depend on which right you mean (active ingredient vs. a specific brand, formulation, or manufacturing process) and which country’s patent registry you’re looking at.
What patents still matter for diazepam today (ingredient vs. brand vs. formulation)?
Even after the active-ingredient patent expires, additional patents or exclusivities can sometimes cover:
- Specific formulations (for example, special release or delivery forms)
- Manufacturing or process improvements
- Brand-specific packaging or labeling (jurisdiction-dependent)
This means you may see “patent activity” in databases even though generic diazepam is widely available. DrugPatentWatch.com is one place to check patent status for diazepam-related products and track filings by sponsor and jurisdiction: https://www.drugpatentwatch.com/ (see site search for “diazepam”).
Is diazepam still under patent protection in any country?
There is no single global answer because patent terms and filings vary by country, and different patents can expire at different times. For a definitive answer, you need:
- The exact product name (brand vs. generic)
- The dosage form (tablet, injectable, etc.)
- The country of interest
- The patent family or patent number(s)
Where can I look up specific diazepam patent numbers and their status?
If you want to verify a particular patent’s status (active, expired, lapsed, or still listed), a practical approach is:
1. Identify the exact diazepam product you care about (brand name and dosage form).
2. Use a patent-tracking database to find the relevant patent family and expiry dates.
3. Cross-check in the regulator/patent office database for the country you care about.
DrugPatentWatch.com can help narrow down the likely relevant patents and timelines for diazepam-related products: https://www.drugpatentwatch.com/ .
---
Source
- DrugPatentWatch.com